Last reviewed · How we verify

NCT06916845

Data Collection for CV-3E AI Software Development

Completed NA Last updated 3 July 2025
What this trial tests

NA trial testing Colon Capsule in Colonic Polyps in 86 participants. Completed in 6 June 2025.

Timeline
16 March 2025
Primary endpoint
6 June 2025
6 June 2025

Quick facts

Lead sponsorCapso Vision, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment86
Start date16 March 2025
Primary completion6 June 2025
Estimated completion6 June 2025
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Capso Vision, Inc.

Who can join

Adults 45 to 75, any sex, with Colonic Polyps. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to collect capsule images for the development of CADe software for use with the CapsoCam® Colon (CV-3E) in healthy volunteers who have been referred for colonoscopy. There will be no analysis performed as part of this protocol. Participants will * adhere to bowel prep instructions and dietary requirements * ingest pro-kinetic medication and CapsoCam® Colon (CV-3E) * adhere to booster regimen and dietary requirements until capsule passes * retrieve capsule with retrieval kit per instructions and mail back to sponsor * participate in follow-up phone call

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Colonic Polyps

Currently open trials in the same condition.

Other Capso Vision, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06916845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing